Each tablet contains potassium chloride 600 mg (potassium 8 mmol, chloride 8 mmol).
Sustained-release potassium chloride supplement.
The tablets consist of potassium chloride crystals partially coated with an inert, insoluble wax, then pressed into a wax matrix. The whole is then sugar-coated (not enteric). The tablet does not integrate. The potassium chloride gradually leaches through the wax. The sustained-release of the therapeutically correct formula, with no enteric association, provides conditions of maximum gastric tolerance and effective absorption for the treatment of all types of potassium deficiency, whether hypochloraemic or hypokalaemic alkolosis. Span-K does not alter normal kidney function; can be used in all age groups; replaces the essential chloride anion and potassium, and so prevents hypochloraemic alkalosis.
Treatment of all types of potassium deficiencies, particularly hypochloraemic or hypokalaemic alkalosis, associated with prolonged or intensive diuretic therapy, eg in hypertension, cardiac failure or massive oedema (potassium replacement is particularly important to patients receiving digitalis, as the clinical response to this drug is seriously affected by hypokalaemia), in renal disease associated with increased potassium excretion, eg nephrotic syndrome; vomiting and diarrhoea , ulcerative colitis, steatorrhoea, diabetes insipidus and uncontrolled diabetes mellitus; ileostomy or colostomy patients, cirrhosis; Cushing's syndrome and dietary insufficiency; during prolonged or intensive treatment with corticosteroids, ACTH or carbenoxolone; hyperaldosteronism in megaloblastic anaemia, during the early stages of treatment. Span-K is indicated if a diet rich in potassium cannot be guranteed.
An average dose is 1 or 2 tabs 2 or 3 times daily, each tablet swallowed whole with a little water, preferably during meals. Where Span-K is given routinely with an average daily maintenance dose of an oral diuretic, 1 or 2 tabs daily may be sufficient.
Severe tissue destruction including burns; advanced renal failure, untreated Addison's disease, acute dehydration, hyperkalaemia; in the presence of obstruction in the digestive tract (eg, resulting from compression of the oesophagus due to dilatation of the left atrium or from stenosis of the gut).
If the patient develops severe vomiting, severe abdominal pains, flatulence or gastrointestinal haemorrhage, Span-K must be withdrawn at once. To prevent the risk of hyperkalaemia, potassium supplements should not be administered with potassium-sparing diuretic agents, eg spironolactone, triamterene or amiloride. In cases of metabolic acidosis, hypokalaemia should not be treated with potassium chloride, but with a potassium salt containing an alkalinising anion (eg, potassium bicarbonate).
Caution is required in cases of chronic renal disease and hepatic cirrhosis because of the risk of hyperkalaemia.
Oral potassium preparations can provoke gastrointestinal disturbances (eg, nausea, vomiting, abdominal pain, diarrhoea). In rare cases, Span-K may also cause these side effects. Should this occur, reduction in dosage or withdrawal of the drug may be necessary.
A12BA01 - potassium chloride ; Belongs to the class of potassium-containing preparations. Used as dietary supplements.
SR tab 600 mg (white, slow release) x 200's.